A5051592498- Mosquito-borne diseases and control
- Malaria Research and Control
- Viral Infections and Outbreaks Research
- vaccines and immunoinformatics approaches
- HIV Research and Treatment
- Patient-Provider Communication in Healthcare
- Ethics in Clinical Research
- Viral Infections and Vectors
- Hepatitis B Virus Studies
- Computational Drug Discovery Methods
- Parasites and Host Interactions
- Vaccine Coverage and Hesitancy
- Complement system in diseases
- Hepatitis Viruses Studies and Epidemiology
- Disaster Response and Management
- Viral Infections and Immunology Research
- Tuberculosis Research and Epidemiology
- Virus-based gene therapy research
- interferon and immune responses
- SARS-CoV-2 and COVID-19 Research
- Drug-Induced Hepatotoxicity and Protection
- Health Policy Implementation Science
- Herpesvirus Infections and Treatments
- Virology and Viral Diseases
- Misinformation and Its Impacts
University of Oxford
2007-2025
Jenner Institute
2014-2025
Churchill Hospital
2014-2017
Vienna Vaccine Safety Initiative
2011-2016
National Institute for Health Research
2015
Oxford Biomedical Research
2015
Heidelberg University
2010-2015
University Hospital Heidelberg
2010-2015
MRC Unit the Gambia
2004-2011
Statens Serum Institut
2009-2011
The West African outbreak of Ebola virus disease that peaked in 2014 has caused more than 11,000 deaths. development an effective vaccine is a priority for control future outbreak.
The 2014 west African Zaire Ebola virus epidemic prompted worldwide partners to accelerate clinical development of replication-defective chimpanzee adenovirus 3 vector vaccine expressing glycoprotein (ChAd3-EBO-Z). We aimed investigate the safety, tolerability, and immunogenicity ChAd3-EBO-Z in Malian US adults, assess effect boosting Malians with modified vaccinia Ankara other filovirus antigens (MVA-BN-Filo).
Background Many malaria vaccines are currently in development, although very few have been evaluated for efficacy the field. Plasmodium falciparum multiple epitope (ME)– thrombospondin-related adhesion protein (TRAP) candidate designed to potently induce effector T cells and so a departure from earlier field terms of their mechanism action. ME-TRAP encode polyepitope string TRAP sporozoite antigen. Two vaccine vectors encoding ME-TRAP, plasmid DNA modified vaccinia virus Ankara (MVA), when...
Vaccination with the recombinant viral vectors chimpanzee adenovirus 63 followed by modified vaccinia Ankara both encoding malaria sequence ME-TRAP conferred 67% protection against infection Plasmodium falciparum in Kenyan adults.
Background Heterologous prime boost immunization with chimpanzee adenovirus 63 (ChAd63) and Modified vaccinia Virus Ankara (MVA) vectored vaccines is a strategy recently shown to be capable of inducing strong cell mediated responses against several antigens from the malaria parasite. ChAd63-MVA expressing Plasmodium falciparum pre-erythrocytic antigen ME-TRAP (multiple epitope string thrombospondin-related adhesion protein) leading vaccine candidate, sterile protection in naïve adults...
The 2014 West African outbreak of Ebola virus disease highlighted the urgent need to develop an effective vaccine. We undertook 2 phase 1 studies assessing safety and immunogenicity viral vector modified vaccinia Ankara vectored Zaire vaccine (MVA-EBO-Z), manufactured rapidly on a new duck cell line either alone or in heterologous prime-boost regimen with recombinant chimpanzee adenovirus type 3 (ChAd3-EBO-Z) followed by MVA-EBO-Z. Adult volunteers United Kingdom (n = 38) Senegal 40) were...
Malaria remains a significant global health burden and vaccine would make substantial contribution to malaria control. Chimpanzee Adenovirus 63 Modified Vaccinia Ankara Multiple epitope thrombospondin adhesion protein (ME-TRAP) vaccination has shown efficacy against sporozoite challenge in malaria-naive European volunteers infection Kenyan adults. Infants are the target age group for vaccination; however, no studies have yet assessed T-cell responses children infants. We enrolled 138 Gambian...
Successful vaccination against intracellular pathogens, including liver-stage Plasmodium falciparum,will require induction of strong antigen-specific lymphocyte responses. The multiple epitope (ME)-thrombospon-din-related adhesion protein (TRAP) construct includes CD8+ and CD4+ cell epitopes from pre-erythrocytic P. falciparumantigens fused in-frame to the entire antigen TRAP. Three carriers for this constructplasmid DNA 2 recombinant nonreplicating poxviruses (modified vaccinia virus Ankara...
Background Plasmodium falciparum Apical Membrane Antigen 1 (PfAMA1) is a candidate vaccine antigen expressed by merozoites and sporozoites. It plays key role in red blood cell hepatocyte invasion that can be blocked antibodies. Methodology/Principal Findings We assessed the safety immunogenicity of recombinant PfAMA1 dose-escalating, phase Ia trial. FVO strain, produced Pichia pastoris, was reconstituted at 10 µg 50 doses with three different adjuvants, Alhydrogel™, Montanide ISA720 AS02...
Background GMZ2 is a fusion protein of Plasmodium falciparum merozoite surface 3 (MSP3) and glutamate rich (GLURP) that mediates an immune response against the blood stage parasite. Two previous phase I clinical trials, one in naïve European adults malaria-exposed Gabonese showed was well tolerated immunogenic. Here, we present data on safety immunogenicity to five year old children, target population for future malaria vaccine efficacy trials. Methodology/Principal Findings Thirty children...
Background Heterologous prime boost immunization with chimpanzee adenovirus 63 (ChAd63) and Modified Vaccinia Virus Ankara (MVA) vectored vaccines is a strategy previously shown to provide substantial protective efficacy against P. falciparum infection in United Kingdom adult Phase IIa sporozoite challenge studies (approximately 20–25% sterile protection similar numbers showing clear delay time patency), greater point trial Kenyan adults. Methodology We conducted the first IIb clinical...
To induce a deployable level of efficacy, successful malaria vaccine would likely benefit from both potent cellular and humoral immunity. These requirements are met by heterologous prime-boost immunization strategy employing chimpanzee adenovirus vector followed modified vaccinia Ankara (MVA), encoding the pre-erythrocytic antigen ME-thrombospondin-related adhesive protein (TRAP), with high immunogenicity significant efficacy in UK adults. We undertook two phase 1b open-label studies adults...
Malaria transmission is in decline some parts of Africa, partly due to the scaling up control measures. If goal elimination be achieved, additional measures including an effective and durable vaccine will required. Studies utilising prime-boost approach deliver viral vectors encoding pre-erythrocytic antigen ME-TRAP (multiple epitope thrombospondin-related adhesion protein) have shown promising safety, immunogenicity efficacy sporozoite challenge studies. More recently, a study Kenyan...
Heterologous prime-boosting with viral vectors encoding the pre-erythrocytic antigen thrombospondin-related adhesion protein fused to a multiple epitope string (ME-TRAP) induces CD8+ T cell-mediated immunity malaria sporozoite challenge in European malaria-naive and Kenyan semi-immune adults. This approach has yet be evaluated children infants. We assessed this vaccine strategy among 138 Gambian Burkinabe four cohorts: 2- 6-year olds The Gambia, 5- 17-month-olds Burkina Faso, 12-month-olds...
SummaryBackgroundMalaria remains a substantial public health burden among young children in sub-Saharan Africa and highly efficacious vaccine eliciting durable immune response would be useful tool for controlling malaria. R21 is malaria comprising nanoparticles, formed from circumsporozoite protein hepatitis B surface antigen (HBsAg) fusion protein, without any unfused HBsAg, administered with the saponin-based Matrix-M adjuvant. This study aimed to assess safety immunogenicity of candidate,...
Naturally acquired immunity to Plasmodium falciparum's asexual blood stage reduces parasite multiplication at microscopically detectable densities. The effect of natural on initial prepatent during the period following a new infection has been uncertain, contributing doubt regarding utility experimental challenge models for blood-stage vaccine trials. Here we present data revealing that rates in semi-immune Gambian adults are substantially lower than malaria-naive participants. This supports...
MethodsWe conducted a randomized controlled trial in Basse and Jahaly Provinces the Upper River Region Central Region, respectively, of Gambia from 15 August 2013 to 12 March 2014.The study was nested within parent -the PRINOGAM trial. 14The aim this determine optimal dosage primaquine required clear gametocytes block disease transmission asymptomatic malaria carriers.Participants were aged 1 year or older seen on day inclusion (day 0, Objective To assess effectiveness multimedia informed...
Background: International guidelines recommend the use of appropriate informed consent procedures in low literacy research settings because written information is not known to guarantee comprehension study information.Objectives: This developed and evaluated a multimedia tool for people with an area where malaria treatment trial was being planned The Gambia. Methods:We document into integrating video, animations audio narrations three major Gambian languages.Acceptability ease were assessed...
The safety and immunogenicity of PfAMA1, adjuvanted with Alhydrogel® was assessed in malaria–experienced Malian adults. malaria vaccine, PfAMA1-FVO [25-545] is a recombinant protein Pichia pastoris-expressed AMA-1 from Plasmodium falciparum FVO clone adsorbed to Alhydrogel®, the control vaccine tetanus toxoid produced formaldehyde detoxified purified toxin. A double blind randomized controlled phase 1 study enrolled followed 40 healthy adults aged 18–55 years Bandiagara, Mali, West Africa,...
Background Heterologous prime-boost vaccination with ChAd63 and MVA encoding ME-TRAP has shown acceptable safety promising immunogenicity in African adult pediatric populations. If licensed, this vaccine could be given to infants receiving routine childhood immunizations. We therefore evaluated responses when co-administered Expanded Programme on Immunization (EPI) vaccines. Methods enrolled 65 Gambian neonates, aged sixteen, eight or one week at first randomized them receive either EPI...
To develop and psychometrically evaluate an audio digitised tool for assessment of comprehension informed consent among low-literacy Gambian research participants.